Flag of the European Union EU Clinical Trials Register Help

Clinical trials for cholangiocarcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: cholangiocarcinoma. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2015-001443-36 Sponsor Protocol Number: ARQ087-101 Start Date*: 2015-08-05
    Sponsor Name:ARQULE INC
    Full Title: A Phase 1/2 Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene Fusion
    Medical condition: Advanced Solid Tumors with FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma with FGFR2 Gene Fusion
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10065143 Malignant solid tumour LLT
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000257-45 Sponsor Protocol Number: MO40094 Start Date*: 2021-07-19
    Sponsor Name:University Hospital Essen
    Full Title: A phase Ib/II single-arm study evaluating the safety and efficacy of combined immunotherapy with mFOLFOX6, bevacizumab and atezolizumab in advanced-stage biliary cancer
    Medical condition: advanced biliary tract cancer (BTC)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002389-41 Sponsor Protocol Number: ADJUBIL Start Date*: 2022-02-25
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
    Full Title: A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer
    Medical condition: biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10042613 - Surgical and medical procedures 10004675 Biliary tract and gallbladder therapeutic procedures HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10048798 Biliary adenoma PT
    21.1 10042613 - Surgical and medical procedures 10061696 Biliary tract operation PT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074878 Hilar cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017620 Gallbladder carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004444-38 Sponsor Protocol Number: GAIN/GEM/CIS Start Date*: 2019-01-11
    Sponsor Name:Krankenhaus Nordwest gGmbH
    Full Title: Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally det...
    Medical condition: incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC))
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025734 Malignant neoplasm of biliary tract, part unspecified LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028982 Neoplasm biliary tract LLT
    20.0 10042613 - Surgical and medical procedures 10004675 Biliary tract and gallbladder therapeutic procedures HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    21.1 10042613 - Surgical and medical procedures 10061962 Gallbladder operation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004411-11 Sponsor Protocol Number: NeoTreme Start Date*: 2023-05-03
    Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck
    Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
    Medical condition: Intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005605-27 Sponsor Protocol Number: TNG908-C101 Start Date*: 2022-09-07
    Sponsor Name:Tango Therapeutics, Inc.
    Full Title: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG908 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
    Medical condition: Phase 1: • Locally advanced or metastatic MTAP-deleted solid tumors (with the exception of gliomas) Phase 2: • Arm 1: Locally advanced or metastatic MTAP-deleted squamous and nonsquamous NSCLC ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    24.0 100000004864 10085300 Squamous non-small cell lung cancer LLT
    21.0 100000004864 10027408 Mesothelioma malignant advanced LLT
    21.0 100000004864 10027409 Mesothelioma malignant localised LLT
    21.1 100000004864 10026667 Malignant peripheral nerve sheath tumor LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    21.1 100000004864 10077846 Cholangiocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002066-24 Sponsor Protocol Number: PrE0204 Start Date*: 2015-08-28
    Sponsor Name:The All Ireland Cooperative Oncology Research Group (ICORG)
    Full Title: A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma
    Medical condition: Advanced or metastatic cholangiocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004448-12 Sponsor Protocol Number: ARQ087-301 Start Date*: 2017-12-18
    Sponsor Name:ARQULE INC
    Full Title: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
    Medical condition: Inoperable or advanced FGFR2 gene fusion positive intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10073078 Intrahepatic cholangiocarcinoma recurrent LLT
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000123-28 Sponsor Protocol Number: IJB-MULTI-MIME-A-2017 Start Date*: 2018-11-14
    Sponsor Name:Institut Jules Bordet
    Full Title: Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial
    Medical condition: esophageal ADC, esophageal SCC, Cholangiocarcinoma, urothelial cancer (progressive after immunotherapy), or endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10055458 Esophageal adenocarcinoma LLT
    20.0 100000004864 10055476 Esophageal squamous cell carcinoma LLT
    20.0 100000004864 10008595 Cholangiocarcinoma NOS LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10014735 Endometrial cancer NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004217-14 Sponsor Protocol Number: P21.128 Start Date*: 2022-11-09
    Sponsor Name:Leiden University Medical Center
    Full Title: FLUOPANC-trial - Intraoperative near-infrared fluorescence imaging in pancreatic- and extrahepatic bile duct tumors using cRGD-ZW800-1 and dedicated imaging systems: A phase II feasibility, dose-ra...
    Medical condition: Pancreatic cancer (pancreatic carcinoma) Extrahepatic bile duct cancer (cholangiocarcinoma)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004778-81 Sponsor Protocol Number: IMMUWHY Start Date*: 2019-10-29
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH
    Full Title: A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (...
    Medical condition: Intrahepatic Biliary Tract Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    20.0 100000004864 10073077 Intrahepatic cholangiocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003709-33 Sponsor Protocol Number: AIO-HEP-0116 Start Date*: 2017-05-04
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A randomized phase II trial of nal-IRI and 5-Fluorouracil compared to 5-Fluorouracil in patients with cholangio- and gallbladder carcinoma previously treated with gemcitabine-based therapies
    Medical condition: advanced, unresectable and metastatic cholangio- and gallbladder carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077846 Cholangiocarcinoma metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017634 Gallbladder neoplasms malignant HLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051667 Metastases to gallbladder PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017614 Gallbladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003217-11 Sponsor Protocol Number: NL82304.058.22 Start Date*: 2023-02-24
    Sponsor Name:Leiden University Medical Center
    Full Title: Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple procedure (SPARROW): a multicenter, randomized controlled trial
    Medical condition: Pancreatic head malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033614 Pancreatic carcinoma resectable LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026319 Malignant neoplasm of pancreatic duct LLT
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008597 Cholangiocarcinoma resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001843-25 Sponsor Protocol Number: BNT141-01 Start Date*: 2023-02-23
    Sponsor Name:BioNTech SE
    Full Title: Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT141 as a monotherapy and...
    Medical condition: CLDN18.2-positive solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015332 Esophageal adenocarcinoma recurrent LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 100000004871 10004676 Biliary tract disease LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004810-16 Sponsor Protocol Number: TPU-TAS-120-101 Start Date*: 2014-04-10
    Sponsor Name:Taiho Oncology Inc
    Full Title: PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) NL (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002113-19 Sponsor Protocol Number: 42756493CAN2002 Start Date*: 2019-10-31
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations
    Medical condition: Advanced solid tumors (other than Urothelial tumors), and FGFR gene alterations.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) FR (Completed) DE (Trial now transitioned) ES (Ongoing) BE (Completed) IT (Completed) Outside EU/EEA SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006386-38 Sponsor Protocol Number: 20210104 Start Date*: 2022-06-02
    Sponsor Name:Amgen, Inc.
    Full Title: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE 301)
    Medical condition: A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055476 Esophageal squamous cell carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073364 Ductal adenocarcinoma of pancreas PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033131 Ovarian carcinoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014720 Endometrial adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008239 Cervical carcinoma recurrent LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) AT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004630-42 Sponsor Protocol Number: TAS-120-301 Start Date*: 2021-01-25
    Sponsor Name:Taiho Oncology Inc
    Full Title: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangem...
    Medical condition: Advanced solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PT (Prematurely Ended) DE (Prematurely Ended) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003656-31 Sponsor Protocol Number: UCL/14/0174 Start Date*: 2015-07-31
    Sponsor Name:University College London
    Full Title: Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers
    Medical condition: Locally advanced biliary tract cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10004586 Bile duct adenocarcinoma non-resectable LLT
    20.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-013408-30 Sponsor Protocol Number: 2009-013408-30 Start Date*: 2010-08-23
    Sponsor Name:University College London
    Full Title: Randomised phase II trial of cediranib (AZD2171) vs. placebo in addition to cisplatin / gemcitabine chemotherapy for patients with advanced biliary tract cancers
    Medical condition: biliary tract carcinomas (including gallbladder cancer and cholangiocarcinomas)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10004595 Bile duct cancer NOS LLT
    17.0 100000004864 10008594 Cholangiocarcinoma non-resectable LLT
    17.0 100000004864 10017617 Gallbladder cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 09:12:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA